Early nutritional support in metastatic gastrointestinal cancer patients planned to be treated with immuno-checkpoint inhibitors: A Prospective Cohort Study.

Early nutritional support in metastatic gastrointestinal cancer patients planned to be treated with immuno-checkpoint inhibitors: A Prospective Cohort Study. - ENTRANCE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043548

Enrollment

Registered

2021-03-10

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years or older; 2) Patients scheduled for induction of immune checkpoint inhibitor treatment(nivolumab or pembrolizumab) 3) Gastrointestinal function is maintained

Exclusion criteria

Exclusion criteria: 1) Patients who have enteral feeding difficulties 2) Severe major organ dysfunction 3) Active multiple primary cancers

Design outcomes

Primary

Measure	Time frame
Association between patient nutritional status and immune status of the patients	—

Secondary

Measure	Time frame
Nutritional status of the patients, efficacy and safety of immuno-checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactNaoki Takegawa

Hyogo cancer Department of Gastroenterology

takegawa@hp.pref.hyogo.jp078-929-1151

Outcome results